Skip to main content
TipRanks
Go Ultimate75% OFF

Harvard Bioscience (HBIO) Ratios

278 Followers

Harvard Bioscience Ratios

HBIO's free cash flow for Q3 2026 was $-1.18M. For the 2026 fiscal year, HBIO's free cash flow was decreased by $-927.00K and operating cash flow was $-248.00K. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio2.200.821.852.202.43
Quick Ratio1.250.400.921.061.34
Cash Ratio0.390.070.160.190.31
Solvency Ratio-0.77-0.090.06-0.030.09
Operating Cash Flow Ratio0.310.030.530.050.05
Short-Term Operating Cash Flow Coverage4.410.042.390.300.39
Net Current Asset Value$ -18.11M$ -18.19M$ -15.25M$ -22.02M$ -17.36M
Leverage Ratios
Debt-to-Assets Ratio0.550.350.310.370.35
Debt-to-Equity Ratio3.220.700.590.750.68
Debt-to-Capital Ratio0.760.410.370.430.41
Long-Term Debt-to-Capital Ratio0.720.000.300.370.35
Financial Leverage Ratio5.832.001.882.011.95
Debt Service Coverage Ratio-7.12-0.060.760.101.86
Interest Coverage Ratio-0.13-1.940.53-2.721.34
Debt to Market Cap1.260.400.160.410.17
Interest Debt Per Share11.0810.961.091.371.45
Net Debt to EBITDA-0.77-27.404.7952.685.45
Profitability Margins
Gross Profit Margin53.01%58.18%58.86%53.66%56.90%
EBIT Margin-60.62%-8.98%0.92%-5.85%1.18%
EBITDA Margin-53.75%-1.57%7.16%0.83%7.59%
Operating Profit Margin-0.73%-6.60%1.69%-6.12%1.74%
Pretax Profit Margin-66.30%-12.39%-2.28%-8.10%-0.12%
Net Profit Margin-65.51%-13.18%-3.04%-8.40%-0.24%
Continuous Operations Profit Margin-65.51%-13.18%-3.04%-8.40%-0.24%
Net Income Per EBT98.80%106.34%133.61%103.67%205.71%
EBT Per EBIT9123.37%187.81%-134.95%132.40%-6.78%
Return on Assets (ROA)-70.81%-9.80%-2.49%-6.55%-0.18%
Return on Equity (ROE)-412.84%-19.58%-4.67%-13.18%-0.35%
Return on Capital Employed (ROCE)-1.08%-8.66%1.71%-5.68%1.51%
Return on Invested Capital (ROIC)-1.04%-5.66%1.60%-5.41%1.45%
Return on Tangible Assets-90.18%-20.96%-5.31%-13.98%-0.37%
Earnings Yield-190.92%-13.50%-1.50%-8.30%-0.10%
Efficiency Ratios
Receivables Turnover5.396.336.976.785.45
Payables Turnover11.148.228.318.1510.44
Inventory Turnover1.951.691.871.991.86
Fixed Asset Turnover18.088.3812.8212.3411.53
Asset Turnover1.080.740.820.780.73
Working Capital Turnover Ratio10.5414.884.463.533.55
Cash Conversion Cycle221.61228.77203.81192.75228.51
Days of Sales Outstanding67.6657.6452.3553.8067.02
Days of Inventory Outstanding186.73215.51195.36183.76196.47
Days of Payables Outstanding32.7844.3843.9044.8134.97
Operating Cycle254.39273.15247.70237.56263.49
Cash Flow Ratios
Operating Cash Flow Per Share1.520.330.330.030.03
Free Cash Flow Per Share1.26-0.420.28-0.01-0.00
Dividend Paid and CapEx Coverage Ratio6.040.446.070.720.94
Capital Expenditure Coverage Ratio6.040.446.070.720.94
Operating Cash Flow Coverage Ratio0.150.030.330.020.02
Operating Cash Flow to Sales Ratio0.080.020.120.010.01
Free Cash Flow Yield18.91%-1.98%5.16%-0.38%-0.03%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-0.52-7.54-66.46-12.05-987.56
Price-to-Sales (P/S) Ratio0.340.982.021.012.39
Price-to-Book (P/B) Ratio2.161.453.111.593.41
Price-to-Free Cash Flow (P/FCF) Ratio5.29-50.3919.37-261.90-3426.72
Price-to-Operating Cash Flow Ratio4.4163.8016.1899.58225.37
Price-to-Earnings Growth (PEG) Ratio-0.00-0.031.02-0.0010.24
Enterprise Value Multiple-1.40-89.7233.04174.2036.98
Enterprise Value65.36M132.25M265.44M164.45M333.56M
EV to EBITDA-1.40-89.7233.04174.2036.98
EV to Sales0.761.402.361.452.81
EV to Free Cash Flow11.64-72.5522.65-375.45-4018.76
EV to Operating Cash Flow9.7191.8418.92142.75264.31
Tangible Book Value Per Share-0.78-0.95-0.00-0.12-0.04
Shareholders’ Equity Per Share3.0914.551.721.742.07
Tax and Other Ratios
Effective Tax Rate0.01-0.06-0.34-0.04-1.06
Revenue Per Share19.5021.622.652.742.95
Net Income Per Share-12.77-2.85-0.08-0.23-0.01
Tax Burden0.991.061.341.042.06
Interest Burden1.091.38-2.471.38-0.10
Research & Development to Revenue0.100.110.100.110.09
SG&A to Revenue0.430.460.200.220.20
Stock-Based Compensation to Revenue-0.020.050.040.040.04
Income Quality-0.12-0.12-4.11-0.12-4.38

Currency in USD